Business Of Biotech
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D.
Dec 30, 2024
Zandy Forbes, Ph.D., is the President & CEO of Meira GTx, blending her expertise in molecular genetics and healthcare investing. She shares insights on risk mitigation in biotech, drawing from her dynamic transition from investment banking to leading a gene therapy company. Forbes discusses the challenges of managing personal fears while navigating investment decisions, the significance of strategic planning, and her company’s advancements in innovative treatments for conditions like blindness. Her unique experiences blend science and finance in the high-stakes biotech landscape.
01:02:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Dr. Zandy Forbes transitioned from academia to hedge fund investment, gaining invaluable insights into risk assessment in biotechnology.
- Meira GTx's strategy emphasizes diverse gene therapy development, patient-centric solutions, and in-house manufacturing for effective and accessible treatments.
Deep dives
Transition from Academia to Investment Banking
Dr. Zandi Forbes experienced a significant shift from her academic career in molecular genetics to the world of investment banking, prompted by an unexpected opportunity. Initially focused on research, she was recruited by a hedge fund where her scientific background opened her eyes to the vast possibilities in biotech beyond conventional academia. The exposure to real-world investment strategies and clinical developments broadened her understanding and ultimately changed her career trajectory. At the hedge fund, she learned valuable lessons on risk assessment, especially regarding the emotional highs and lows of investment decisions, a stark contrast to the more exploratory nature of scientific inquiry.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
